Do surface active parenteral formulations cause inflammation?

被引:3
|
作者
Soderberg, Lars [1 ,2 ,3 ]
Engblom, Johan [1 ,2 ]
Lanbeck, Peter [4 ]
Wahlgren, Marie [5 ]
机构
[1] Malmo Univ, Dept Biomed Sci, SE-20506 Malmo, Sweden
[2] Malmo Univ, Biofilms Res Ctr Biointerfaces, SE-20506 Malmo, Sweden
[3] Lund Univ, Dept Clin Sci, Clin Physiol & Nucl Med Unit, Malmo, Sweden
[4] Lund Univ, Dept Clin Sci, Infect Dis Res Unit, Malmo, Sweden
[5] Lund Univ, Dept Food Technol, SE-22100 Lund, Sweden
关键词
Inflammation; Surface activity; Parenteral formulation; Antibiotic; Anesthetic; Fatty acid; FREE-FATTY-ACIDS; ENDOTHELIAL-CELLS; MYOCARDIAL-INFARCTION; INFUSION PHLEBITIS; MUSCLE DAMAGE; ANIMAL-MODELS; ANTIBIOTICS; INJECTION; LACTATE;
D O I
10.1016/j.ijpharm.2015.02.045
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Local irritation and inflammation at the site of administration are a common side effect following administration of parenteral formulations. Biological effects of surface (interfacial) activity in solutions are less well investigated than effects caused by other physico-chemical parameters such as pH and osmolality. The interfacial activity in different systems, including human plasma, typical amphiphilic substances with fundamental biological relevance such as free fatty acids, anesthetic depot formulations and six different antibiotics was measured. The relative interfacial pressure, and/or concentration of active substance, required to obtain 50% of the maximal attainable effect in terms of interfacial pressure were calculated. The aim was to test the hypothesis that these parameters would allow comparison to biological effects reported in in vivo studies on the investigated substances. The highest interfacial activity was found in a triglyceride/plasma system. Among the antibiotic tested, the highest interfacial activities were found in erythromycin and dicloxacillin, which is in accordance with previous clinical findings of a high tendency of infusion phlebitis and cell toxicity. Independently of investigated system, biological effects were minimal below a 15% relative increase of interfacial activity. Above 35-45% the effects were severe. Interfacial activity in parenteral formulations may well cause damages to tissues followed by inflammation. (C) 2015 Elsevier B. V. All rights reserved.
引用
收藏
页码:246 / 251
页数:6
相关论文
共 50 条
  • [1] Parenteral formulations
    Holm, Rene
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 200
  • [2] Standardized Hospital Compounded Parenteral Nutrition Formulations Do Not Guarantee Safety
    Poh, Bee Yen
    Benajmin, Suzanne
    Hayward, Thomas Z., III
    AMERICAN SURGEON, 2011, 77 (06) : E109 - E111
  • [3] TEMAZEPAM PARENTERAL FORMULATIONS
    MCCAFFERTY, DF
    WOOLFSON, AD
    HALLIDAY, NJ
    LAUNCHBURY, AP
    BRITISH JOURNAL OF ANAESTHESIA, 1986, 58 (07) : P810 - P810
  • [4] Cyclodextrins in Parenteral Formulations
    Loftsson, Thorsteinn
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (02) : 654 - 664
  • [5] BUFFY COATS DO NOT CAUSE INFLAMMATION - REPLY
    CHRISTOPHERS, E
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1984, 10 (06) : 1064 - 1064
  • [6] Compendium of excipients for parenteral formulations
    Powell, MF
    Nguyen, T
    Baloian, L
    PDA JOURNAL OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY, 1998, 52 (05): : 238 - 311
  • [7] STABILITY OF TEMAZEPAM IN PARENTERAL FORMULATIONS
    MCCAFFERTY, DF
    WOOLFSON, AD
    LAUNCHBURY, AP
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 31 (1-2) : 9 - 13
  • [8] Surface-modified and conventional nanocapsules as novel, formulations for parenteral delivery of halofantrine
    Furtado Mosqueira, Vanessa Carla
    Legrand, Philippe
    Barratt, Gillian
    JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2006, 6 (9-10) : 3193 - 3202
  • [9] Fungal spores as such do not cause nasal inflammation in mold exposure
    Roponen, M
    Seuri, M
    Nevalainen, A
    Hirvonen, MR
    INHALATION TOXICOLOGY, 2002, 14 (05) : 541 - 549
  • [10] Surface Functionalised Parenteral Nanoemulsions for Active and Homotypic Targeting to Melanoma
    Foglietta, Federica
    Bozza, Annalisa
    Ferraris, Chiara
    Cangemi, Luigi
    Bordano, Valentina
    Serpe, Loredana
    Martina, Katia
    Lazzarato, Loretta
    Pizzimenti, Stefania
    Grattarola, Margherita
    Cucci, Marie Angele
    Dianzani, Chiara
    Battaglia, Luigi
    PHARMACEUTICS, 2023, 15 (05)